Navigation Links
Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Date:5/8/2008

42 2,080

Shareholders' equity 2,053 1,866

Reconciliation of Adjusted Earnings to GAAP Earnings; EBITDA

To supplement its consolidated financial statements presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the Company is providing the supplemental financial information contained below to reflect (1) the adjusted earnings per share effect of certain unusual or infrequent charges or benefits that were taken or received in the quarter ended March 31, 2008, and (2) the calculation of EBITDA for each period presented.

Adjusted earnings per share and EBITDA are non-GAAP financial measures. The Company is providing this information, however, because it believes that such information is useful to both management and investors in that it facilitates analysis by both management and investors in evaluating the Company's performance and trends. The presentation of this additional information is not meant to be considered in isolation of, or as a substitute for, results prepared in accordance with GAAP.

Barr Pharmaceuticals, Inc. Selected Adjusted Financial Data

(in millions, except per share amounts)

Three Months Ended March 31, 2008

Adjusted

GAAP Adjustments Earnings

Revenues:

Product sales $565 - $565

Alliance and

development revenue 32 - 32

Other revenue 11 (5) (b) 6

Total revenues 608 (5) 603

Costs and expenses:

Cost of sales 275 (55) (b),(c),(d),(f) 220

Selling, general and

adm
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
2. Dendreon Reports First Quarter 2008 Financial Results
3. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. iCAD Reports First Quarter 2008 Financial Results
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
10. Onyx Pharmaceuticals Reports 2008 First Quarter Results
11. AtriCure Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4First-in-class treatment for acute leukemia 2First-in-class treatment for acute leukemia 3Self-destructing bacteria improve renewable biofuel production 2Self-destructing bacteria improve renewable biofuel production 3New MedPredict Report Reveals Top Alzheimers Experts Insights on Diagnostics and Treatments in Development Pipeline 12601 1New MedPredict Report Reveals Top Alzheimers Experts Insights on Diagnostics and Treatments in Development Pipeline 12601 2Healthcare Travel Congress 2009 3A Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 48752 1Healthcare Travel Congress 2009 3A Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 48752 2Healthcare Travel Congress 2009 3A Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 48752 3Preparing the Americas 3A The Outlook for 2009s Emergency Threats 48748 1Preparing the Americas 3A The Outlook for 2009s Emergency Threats 48748 2